Nanobody dimers linked via C-terminally engineered cysteins

US11021544B2 · kind B2 · utility

Assignee

• Ablynx N.V. · BE

Inventors

• Carlo Boutton · Wielsbeke, BE
• Daniel Janssen · Puurs, BE
• Peter Casteels · Bambrugge, BE
• Peter Schotte · Zevergem, BE
• Francis Descamps · Roeselare, BE

Key dates

• Filing date: Feb 5, 2016
• Grant date: Jun 1, 2021
• Expiry date: Sep 11, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/77
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.